- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06296706
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
A Multicenter, Randomized, Controlled Phase III Clinical Study of Docetaxel for Injection (Albumin-bound) Versus Taxotere in Gastric Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Clinical Trials Information Group officer
- Phone Number: 86-0311-69085587
- Email: ctr-contact@cspc.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18-75 years (inclusive) (Whichever is on the day of signing the informed consent form).
- Gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction confirmed by histology or cytology.
- Locally advanced or metastatic gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction that has progressed after receiving first-line systematic treatment (defined as platinum/fluorouracil containing dual drug chemotherapy, with or without immunotherapy).
- Evidence of disease progression on imaging during or after the last systemic treatment as confirmed by investigator.
- At least one assessable lesion according to RECIST V1.1; the area should not have received previous radiotherapy, or there should be evidence of definite progress of the lesion after completion of radiotherapy.
- Previous history with positive Her-2 expression requires anti-Her-2 medication; unknown Her-2 expression should define Her-2 status before enrollment.
- Adequate main organ function.
- Eastern Cooperative Oncology Group (ECOG) score 0-1.
- Expected lifetime≥ 3 months.
- Female patients of childbearing age must have a negative serum pregnancy test within 7 days prior to randomization; patients must agree to take adequate contraception from signing of ICF through 6 months after last dose, during which time women are not breastfeeding; male patients must agree to contraception and refuse sperm donation.
- Fully understand this clinical trial and willing to sign a written informed consent form.
Exclusion Criteria:
- Diagnosed as Krukenberg tumor, unless radical resection has been performed and there is no visible tumor residue.
- Medical history of other malignant tumors or other active malignant tumors within 5 years prior to randomization (cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, etc. can be included).
- Uncontrolled serous cavity effusion requiring frequent drainage or medical intervention within 14 days before randomization (Additional intervention is required within 2 weeks after intervention, such as pleural effusion, abdominal effusion, pericardial effusion, etc., excluding exfoliative cytology testing of exudate).
- Patients with central nervous system metastasis.
- Patients who have used paclitaxel/docetaxel in the past (except patients with disease progression more than one year after neoadjuvant/adjuvant treatment with paclitaxel/docetaxel).
- Patients whose previous medical history shows dMMR/MSI-H (deficient Mismatch Repair or High Microsatellite Instability) and who have not received immunotherapy in the past are not suitable for enrollment, and those whose dMMR/MSI status is unknown need to clarify the status before enrollment.
- History of serious cardiovascular or cerebrovascular disease, including but not limited to:
1) Serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, third degree atrioventricular block, etc; 2) Acute coronary syndrome, congestive heart failure, stroke, or other level 3 or higher cardiovascular events occurring within 6 months before randomization; 3) The New York Heart Association (NYHA) heart function rating of ≥ Grade Ⅱ or left ventricular ejection fraction (LVEF) of<50%; 4) Long QTc syndrome or QTc interval>480 milliseconds, as well as the use of any known concomitant medication that can prolong the QT interval; 5) Poor control of hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening period).
8. History of gastrointestinal perforation and/or fistula within 6 months before randomization.
9. Patients with active hepatitis B(Hepatitis B surface antigen (HBsAg) or HBcAb positive, and in the active phase of hepatitis B (HBV-DNA ≥ 10^4 cps/mL or ≥ 2000 IU/mL)), hepatitis C(Hepatitis C antibody (Anti HCV) positive and tested positive for HCV RNA by PCR) or HIV.
10. Patients with severe chronic or active infections that require systemic antimicrobial, antifungal, or antiviral therapy within 14 days before randomization. Note: Patients with viral hepatitis are allowed to receive antiviral treatment.
11. Tuberculosis treatment history within 2 years before randomization. 12. Patients with gastrointestinal obstruction and active inflammatory bowel disease within 28 days before randomization.
13. Toxic reaction caused by any previous treatment has not recovered to level 1 or below (CTCAE5.0) (excluding anemia, alopecia, fatigue, poor appetite, or other toxicities that the investigator deems to have no safety risk to patients).
14. Received major organ surgery or invasive intervention treatment within 28 days before randomization. Or planned to undergo systematic or local tumor resection surgery during the study period.
15. Received intravenous chemotherapy or biopolymer therapy within 28 days before randomization. Or received oral chemotherapy, immunotherapy (such as interleukin, interferon, thymosin, etc.), hormone therapy, small molecule targeted therapy, or any experimental intervention within 14 days or 5 half-lives (whichever is shorter) before the first treatment. Received traditional Chinese medicine or traditional Chinese patent medicines with anti-tumor indications within 14 days before randomization.
16. Have received powerful CYP3A4 inhibitor or inducer within 14 days before randomization.
17. Allergic to and/or contraindication to albumin or docetaxel. 18. Known allergy and/or contraindication to glucocorticoids (including but not limited to active gastrointestinal ulcers, severe hypertension, severe hypokalemia, glaucoma, etc).
19. Patients with psychiatric neurological disorders that may affect trial adherence, or patients with a history of drug dependence/alcohol dependence.
20. Patients participated in another clinical study at the same time, unless it is an observational (non-intervention) clinical study or is in the follow-up period of an intervention study.
21. Other situations that the investigator thinks are not suitable for patients in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Docetaxel for Injection (Albumin-bound)
Docetaxel for Injection (Albumin-bound) will be administrated by intravenous infusion once every 3 weeks.
|
Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
Other Names:
|
Active Comparator: Taxotere (Docetaxel)
Taxotere will be administrated by intravenous infusion once every 3 weeks.
|
Taxotere, by intravenous infusion, every 3 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Overall survival (OS)
|
At the end of Cycle 1(each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR by IRC
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Overall response rate (ORR) by Independent Review Committee (IRC)
|
At the end of Cycle 1(each cycle is 21 days)
|
ORR by investigator
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Overall response rate (ORR) by investigator
|
At the end of Cycle 1(each cycle is 21 days)
|
PFS
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Progression-Free-Survival (PFS) by Independent Review Committee (IRC) and investigator
|
At the end of Cycle 1(each cycle is 21 days)
|
DCR
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Disease control rate (DCR) by Independent Review Committee (IRC) and investigator
|
At the end of Cycle 1(each cycle is 21 days)
|
DoR
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Duration of Response (DoR) by Independent Review Committee (IRC) and investigator
|
At the end of Cycle 1(each cycle is 21 days)
|
AE and SAE
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
|
At the end of Cycle 1(each cycle is 21 days)
|
Plasma concentration of docetaxel (free and total)
Time Frame: At the end of Cycle 1(each cycle is 21 days)
|
Plasma concentration of docetaxel (free and total)
|
At the end of Cycle 1(each cycle is 21 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ruihua Xu, Doctor, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
Other Study ID Numbers
- HB1801-010
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Docetaxel for injection (Albumin-bound)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingPancreatic CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruitingAdvanced Solid TumorsChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingGastric Adenocarcinoma | Adenocarcinoma of Gastroesophageal JunctionChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced Unresectable Esophageal Squamous CarcinomaChina
-
China Medical University, ChinaRecruiting
-
Sun Yat-sen UniversityJiangsu HengRui Medicine Co., Ltd.UnknownNon-Small Cell Lung CancerChina
-
Sun Yat-sen UniversityShanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.RecruitingEsophageal Small Cell CarcinomaChina
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdNot yet recruiting
-
Peking UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingGastric Cancer | Adenocarcinoma of Esophagogastric JunctionChina
-
Fuzhou General HospitalUnknownNasopharyngeal CarcinomaChina